Concourse Financial Group Securities, Inc. Intellia Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 3,047 shares of NTLA stock, worth $31,079. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,047
Previous 2,526
20.63%
Holding current value
$31,079
Previous $56,000
10.71%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding NTLA
# of Institutions
314Shares Held
91.5MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$125 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$98.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$97.9 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$52.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$50.5 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $775M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...